Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Pechala's Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC To Buy U.S. Cancer Firm For Up To $500 Million-Reuters

Monday, 26 Aug 2013 05:08am EDT 

Reuters reported that AstraZeneca PLC agreed to acquire privately held U.S. biotech company Amplimmune for up to $500 million. AstraZeneca's MedImmune biotech unit will acquire 100%of Amplimmune‚Äôs shares for an initial $225 million and a deferred consideration of up to $275 million based on reaching predetermined development milestones. 

Company Quote

-78.5 -1.63%
17 Apr 2015